Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer.
Johnson RM, Qu X, Lin CF, Huw LY, Venkatanarayan A, Sokol E, Ou FS, Ihuegbu N, Zill OA, Kabbarah O, Wang L, Bourgon R, de Sousa E Melo F, Bolen C, Daemen A, Venook AP, Innocenti F, Lenz HJ, Bais C. Johnson RM, et al. Among authors: huw ly. Nat Commun. 2022 Sep 19;13(1):5478. doi: 10.1038/s41467-022-33172-5. Nat Commun. 2022. PMID: 36117191 Free PMC article.
Low-pass Whole-genome Sequencing of Circulating Cell-free DNA Demonstrates Dynamic Changes in Genomic Copy Number in a Squamous Lung Cancer Clinical Cohort.
Chen X, Chang CW, Spoerke JM, Yoh KE, Kapoor V, Baudo C, Aimi J, Yu M, Liang-Chu MMY, Suttmann R, Huw LY, Gendreau S, Cummings C, Lackner MR. Chen X, et al. Among authors: huw ly. Clin Cancer Res. 2019 Apr 1;25(7):2254-2263. doi: 10.1158/1078-0432.CCR-18-1593. Epub 2019 Jan 7. Clin Cancer Res. 2019. PMID: 30617129
Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma.
Powles T, Lackner MR, Oudard S, Escudier B, Ralph C, Brown JE, Hawkins RE, Castellano D, Rini BI, Staehler MD, Ravaud A, Lin W, O'Keeffe B, Wang Y, Lu S, Spoerke JM, Huw LY, Byrtek M, Zhu R, Ware JA, Motzer RJ. Powles T, et al. Among authors: huw ly. J Clin Oncol. 2016 May 10;34(14):1660-8. doi: 10.1200/JCO.2015.64.8808. Epub 2016 Mar 7. J Clin Oncol. 2016. PMID: 26951309 Free PMC article. Clinical Trial.
A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study).
Makker V, Recio FO, Ma L, Matulonis UA, Lauchle JO, Parmar H, Gilbert HN, Ware JA, Zhu R, Lu S, Huw LY, Wang Y, Koeppen H, Spoerke JM, Lackner MR, Aghajanian CA. Makker V, et al. Among authors: huw ly. Cancer. 2016 Nov 15;122(22):3519-3528. doi: 10.1002/cncr.30286. Epub 2016 Sep 7. Cancer. 2016. PMID: 27603005 Free PMC article.
The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population.
Wilson TR, Yu J, Lu X, Spoerke JM, Xiao Y, O'Brien C, Savage HM, Huw LY, Zou W, Koeppen H, Forrest WF, Fridlyand J, Fu L, Tam R, Schleifman EB, Sumiyoshi T, Molinero L, Hampton GM, O'Shaughnessy JA, Lackner MR. Wilson TR, et al. Among authors: huw ly. NPJ Breast Cancer. 2016 Jul 13;2:16022. doi: 10.1038/npjbcancer.2016.22. eCollection 2016. NPJ Breast Cancer. 2016. PMID: 28721382 Free PMC article.
Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial.
Budde LE, Olszewski AJ, Assouline S, Lossos IS, Diefenbach C, Kamdar M, Ghosh N, Modi D, Sabry W, Naik S, Mehta A, Nakhoda SK, Smith SD, Dorritie K, Jia T, Pham S, Huw LY, Jing J, Wu H, Ead WS, To I, Batlevi CL, Wei MC, Chavez JC. Budde LE, et al. Among authors: huw ly. Nat Med. 2024 Jan;30(1):229-239. doi: 10.1038/s41591-023-02726-5. Epub 2023 Dec 10. Nat Med. 2024. PMID: 38072960 Free PMC article. Clinical Trial.
Systems-based digital twins to help characterize clinical dose-response and propose predictive biomarkers in a Phase I study of bispecific antibody, mosunetuzumab, in NHL.
Susilo ME, Li CC, Gadkar K, Hernandez G, Huw LY, Jin JY, Yin S, Wei MC, Ramanujan S, Hosseini I. Susilo ME, et al. Among authors: huw ly. Clin Transl Sci. 2023 Jul;16(7):1134-1148. doi: 10.1111/cts.13501. Epub 2023 Mar 23. Clin Transl Sci. 2023. PMID: 36908269 Free PMC article. Clinical Trial.
Combination of Atezolizumab and Tazemetostat in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results From a Phase Ib Study.
Palomba ML, Cartron G, Popplewell L, Ribrag V, Westin J, Huw LY, Agarwal S, Shivhare M, Hong WJ, Raval A, Chang AC, Penuel E, Morschhauser F. Palomba ML, et al. Among authors: huw ly. Clin Lymphoma Myeloma Leuk. 2022 Jul;22(7):504-512. doi: 10.1016/j.clml.2021.12.014. Epub 2021 Dec 24. Clin Lymphoma Myeloma Leuk. 2022. PMID: 35151584 Free article. Clinical Trial.
21 results